News

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

by

HAMILTON, ON and BOSTON, June 7, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 68,000 shares of its common stock to two … Read more

Aurora Cannabis to Host Third Quarter and Fiscal Year 2023 Investor Conference Call and File Related Year End Information

by

NASDAQ | TSX: ACB EDMONTON, AB, June 7, 2023 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, announced today that it has scheduled a conference call to discuss the results for its third quarter and full fiscal year 2023 on Wednesday, June … Read more

Prenosis Inc. Receives BARDA Contract to Study Utility of Its Sepsis Diagnostic Tool

by

The Sepsis ImmunoScore™ is a pathogen-agnostic, host-based digital diagnostic that uses Artificial Intelligence/Machine Learning (AI/ML) to predict sepsis based on a combination of clinical parameters and protein biomarkers CHICAGO, June 7, 2023 /PRNewswire/ — Prenosis Inc., an artificial intelligence company enabling precision medicine in acute care, announced today it has been awarded a contract from … Read more

An Innovative Module Enhancing Brain MRI Acquisition Efficiency and Quality

by

ST. LOUIS, June 7, 2023 /PRNewswire/ — Turing Medical Technologies, Inc. (formerly NOUS Imaging, Inc.), a leading neuroimaging software company, announced today at ISMRM 2023 in Toronto the launch of FIRMM-pix: a novel in-bore visual biofeedback module to actively reduce head motion during brain MRI. A complement to Turing’s existing FIRMM software, FIRMM-pix may further … Read more

Global Wound Irrigation Solution Market to Surpass USD 2.01 Bn by 2031

by

PUNE, India, June 7, 2023 /PRNewswire/ — According to a recent market study published by Growth Market Reports, titled, “Global Wound Irrigation Solution Market Segments – By Type (Wetting Agents and Antiseptics), By Type of Wound (Burns, Diabetic Foot Ulcer, Pressure Ulcer, Venous Ulcer, Surgical Wounds, Others), By Application (Acute Care Hospitals, Ambulatory Surgical Center, Wound … Read more

Digital Science boosts pharma industry support following OntoChem acquisition

by

In a sea of information, AI-based solutions will help to focus industry’s R&D LONDON and HALLE, Germany, June 7, 2023 /PRNewswire/ — Digital Science is positioning itself to play an even greater role in the pharmaceutical industry’s all-important drug discovery, by helping industry sift through a sea of information and focus on the research that matters. … Read more

Increasing Air Pollution Drives Adoption

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “United Kingdom Air Purifiers Market By Filter Type (HEPA, Prefilter + HEPA, Prefilter + HEPA + Activated Carbon, & Others (HEPA + Ionizer, Prefilter + Activated Carbon, Prefilter)), By End Use, By Distribution Channel, By Region, By Company, Forecast & Opportunities, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering. The … Read more

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

by

Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial (NCT04563026) investigating larsucosterol for the treatment of patients … Read more

Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicines

by

Company has built leading edge tissue-targeted Lipid Nanoparticle (ttLNP) technology to enable a new generation of highly targeted genomic medicines Participating venture investors include Mass Ave Capital, 5Y Capital, and HIKE Capital Advancing groundbreaking scientific research program for systemic delivery of mRNA to multiple targeted tissues in pre-clinical models, including first-ever data demonstrating highly efficient … Read more

First Commercially Available CD137 Antibody in Next 6 to 7 Years

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023” report has been added to ResearchAndMarkets.com’s offering. The therapeutic potential of CD137 has been investigated exhaustively and has now been confirmed as studies from running clinical and research studies emerge. Many companies are now developing agonists against this receptor … Read more